Do you want to read an article? Please log in or register.
Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial
Hepatology
Related content
RECOMMENDED
Inflammatory Bowel Disease
Position Paper: IOlBD Evidence-based Consensus on the Use of Artificial Intelligence for Assessment of Endoscopic and Histologic Endpoints in Clinical Trials of Inflammatory Bowel Disease
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis
Dignass A, Narula N, Pratap K, Danese S, Dotan I, Iacucci M, Jairath V, Loftus EV Jr, Magro F, Mantzaris G, Peyrin-Biroulet L, Rubin DT, Sands BE, Turner D, Reinisch W, International Organization for the Study of IBD
doi: 10.1093/ecco-jcc/jjag007
Helicobacter Pylori
Tegoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial
Helicobacter
Park JY, Hong SJ, Choi IJ, Baik GH, Kim SM, Park JJ, Jeon SW, Kim KO, Lee SK, Jung HY, Oh JH, Park CH, Kim SW, Shim KN, Jee SR, Moon HS, Moon JS, Choi CW, Lee WS, Kim JG
doi: 10.1111/hel.70106
Gastrointestinal Cancer
Time-dependent recurrence patterns after curative resection for stage II/III colorectal cancer: An integrated analysis of four phase III randomized controlled trials (JCOG2310A-S4)
Eur J Cancer
Tashiro K, Osumi H, Kataoka K, Shimada Y, Inomata M, Hamaguchi T, Takii Y, Suwa Y, Mizusawa J, Sano Y, Suto T, Murata K, Adachi T, Ueno H, Ikeda S, Komori K, Shiozawa M, Tsukamoto S, Takashima A, Kanemitsu Y
doi: 10.1016/j.ejca.2026.116957
Gastrointestinal Cancer
Transanal total mesorectal excision versus laparoscopic total mesorectal excision for mid and low rectal cancer (COLOR III): short-term outcomes of an international, multicentre, phase 3, randomised, controlled, non-inferiority trial
Lancet Gastroenterol Hepatol
Tuynman JB, Yao H, Moolenaar LR, Sietses C, Hompes R, Aigner F, Caycedo-Marulanda A, Chen CC, Deeb M, Doornebosch PG, Feng B, Foo CC, Fürst A, Ito M, de Lacy FB, Leão P, Maykel JA, Muratore A, van Oostendorp SE, Park SC, Pędziwiatr M, Ren M, Seitinger G, Stockmann HBAC, Talsma AK, Türler A, Tong W, Wang Q, Xu Q, Zhang H, van Waesberghe JTM, Ali M, Twisk JWR, Zhang Z, de Lacy AM, Hanna GB, Bonjer HJ, COLOR III Study Group
doi: 10.1016/S2468-1253(26)00022-1
Gastrointestinal Cancer
Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma: The Phase 3 TORCH Randomized Clinical Trial
JAMA Oncol
Lyu N, Yi JZ, Wu XT, Zhang YM, Pan T, Mu LW, Chen S, Wang JL, Xu J, Tan GJ, Zhang YN, Gao ZQ, Ou-Yang ZX, Wu WJ, Song YJ, Deng HJ, He M, Jiang YQ, Chen QF, Li JB, Shi M, Chen MS, Zhao M
doi: 10.1001/jamaoncol.2026.2366
Gallbladder and Biliary Diseases
Elafibranor in primary biliary cholangitis: two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trial
J Hepatol
Kowdley KV, Bowlus CL, Levy C, Akarca U, Alvares-da-Silva MR, Andreone P, Arrese M, Corpechot C, Elbeshbeshy H, Francque S, Heneghan MA, Invernizzi P, Jacobson IM, Jones D, Kremer AE, Kruger FC, Kugelmas M, Lawitz E, Mayo MJ, Shiffman ML, Sonderup M, Swain MG, Valera JM, Vierling JM, Villagrasa A, Villamil A, Antunes N, Raskino C, Sleiman M, Cranham V, Miller B, Schattenberg JM
doi: 10.1016/j.jhep.2026.08.016
Gastrointestinal Cancer
Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial
J Clin Oncol
Mo S, Zhou C, Ma M, Luo W, Li Y, Lu P, Tang P, Li Y, Ma X, Hu X, Cheng C, Yang J, Zhuo C, Jian J, Yu C, Ding J, Xiong C, Jiang F, Mu R, Lu Z, Yu J, Jin S, Luan J, Li X, Cai S, Zou H, Li Y, Li Q, Liu F, Ding C, Peng J
doi: 10.1200/JCO-25-03009
Further Publications
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial
J Gastroenterol Hepatol
Matono T, Tada T, Hiraoka A, Hirooka M, Nakamura Y, Yoshida O, Kariyama K, Nouso K, Tani J, Morishita A, Atsukawa M, Itokawa N, Okubo T, Arai T, Takaguchi K, Tsutsui A, Nagano T, Itobayashi E, Nishimura T, Fukunishi S, Enomoto H, Tsuji K, Tanaka K, Ishikawa T, Tajiri K, Tanaka H, Toyoda H, Koshiyama Y, Ogawa C, Hatanaka T, Kanayama Y, Kakizaki S, Kawata K, Noritake H, Naganuma A, Kosaka H, Matsui K, Kaibori M, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tamai H, Okamura J, Komatsu S, Matsuura T, Nakamura S, Ueda Y, Kim SK, Ohama H, Tada F, Fukumoto T, Hiasa Y, Kudo M, Kumada T
doi: 10.1111/jgh.70422
RECOMMENDED
Further Publications
Treatment of disorders of gut-brain interaction with peppermint oil and caraway oil combination Menthacarin : A phase IV clinical trial
★ 1
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Wien Med Wochenschr
Linas I, Vavricka SR, Langhorst J, Pohl D, Stracke B, Zimmermann A, Funk P, Schiefke I, Madisch A
doi: 10.1007/s10354-025-01119-2